scout
Opinion|Videos|April 12, 2024

KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME